BIOMARKER:

U2AF1 mutation

Entrez ID:

Related biomarkers:

‹

›

U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks (NewC2)	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks - (New C3)
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks (NewC2)	CA-4948 Sensitive: C2 – Inclusion Criteria EHA 2022 - 2 weeks - (New C3)
U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials	cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials	cytarabine Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials	decitabine Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	U2AF1 mutation U2AF1 mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV 075 Sensitive: C3 – Early Trials	venetoclax + ABBV 075 Sensitive: C3 – Early Trials